PCSK9 and prostate carcinoma: Leave-one-out analyses provided consistent evidence of an association between genetically proxied PCSK9 inhibition and risk of prostate cancer, suggesting that the overall estimate was not driven by a single influential variant (S2 Fig and S7 Table).